NEW YORK (GenomeWeb News) — Hologic reported after the close of the market on Wednesday a 2 percent increase in fiscal second quarter revenues despite a 2 percent decrease in sales for its Diagnostics segment.

For the three months ended March 29, the Bedford, Mass.-based company reported revenues of $625 million compared to $612.7 million in the same quarter last year but besting the average Wall Street estimate of $609 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.